ABT 📈 Abbott Laboratories - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000

ABT: Pharmaceuticals, Diagnostic Tools, Nutritionals, Medical Devices

A leading healthcare company, Abbott Laboratories is dedicated to improving lives through innovative products and solutions. With a rich history dating back to 1888, the company operates globally, discovering, developing, manufacturing, and selling a wide range of healthcare products.

Abbott's diverse portfolio is divided into four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company's pharmaceutical offerings include generic medications for various conditions, such as pancreatic exocrine insufficiency, irritable bowel syndrome, and hormone replacement therapy. Additionally, Abbott provides anti-infective medications, influenza vaccines, and products that regulate the physiological rhythm of the colon.

In the realm of diagnostic products, Abbott offers a comprehensive range of solutions, including laboratory and transfusion medicine systems, molecular diagnostics, point-of-care systems, and rapid diagnostics. These products enable healthcare professionals to accurately diagnose and monitor various conditions, such as infectious diseases, cardiometabolic disorders, and diabetes. Abbott's diagnostic portfolio also includes remote patient monitoring and consumer self-test systems, as well as informatics and automation solutions for laboratories.

The company's nutritional products cater to both pediatric and adult needs, providing essential nutrients for healthy growth and development. Furthermore, Abbott's medical devices segment offers a range of innovative solutions for cardiovascular diseases, including rhythm management, electrophysiology, heart failure, vascular, and structural heart devices. The company also provides diabetes care products, such as glucose and blood glucose monitoring systems, as well as neuromodulation devices for managing chronic pain and movement disorders.

Headquartered in North Chicago, Illinois, Abbott Laboratories continues to drive innovation and improve healthcare outcomes worldwide. With a strong commitment to advancing healthcare, the company remains a trusted partner for healthcare professionals, patients, and consumers alike.

Additional Sources for ABT Stock

ABT Stock Overview

Market Cap in USD 203,157m
Sector Healthcare
Industry Medical Devices
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception 1978-01-13

ABT Stock Ratings

Growth 5y 33.0%
Fundamental 58.0%
Dividend 60.2%
Rel. Performance Sector 0.05
Analysts 4.22/5
Fair Price Momentum 110.95 USD
Fair Price DCF 96.75 USD

ABT Dividends

Dividend Yield 12m 1.89%
Yield on Cost 5y 2.81%
Annual Growth 5y 9.77%
Payout Consistency 96.55%

ABT Growth Ratios

Growth Correlation 3m 53.2%
Growth Correlation 12m 33.3%
Growth Correlation 5y 32.9%
CAGR 5y 8.21%
CAGR/Mean DD 5y 0.58
Sharpe Ratio 12m 0.56
Alpha -13.35
Beta 0.76
Volatility 19.19%
Current Volume 4794.9k
Average Volume 20d 5008.1k
What is the price of ABT stocks?
As of December 04, 2024, the stock is trading at USD 116.29 with a total of 4,794,886 shares traded.
Over the past week, the price has changed by -1.42%, over one month by -1.16%, over three months by +1.90% and over the past year by +12.76%.
Is Abbott Laboratories a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Abbott Laboratories (NYSE:ABT) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.99 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABT as of December 2024 is 110.95. This means that ABT is currently overvalued and has a potential downside of -4.59%.
Is ABT a buy, sell or hold?
Abbott Laboratories has received a consensus analysts rating of 4.22. Therefor, it is recommend to buy ABT.
  • Strong Buy: 13
  • Buy: 8
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecast for ABT stock price target?
According to ValueRays Forecast Model, ABT Abbott Laboratories will be worth about 122 in December 2025. The stock is currently trading at 116.29. This means that the stock has a potential upside of +4.89%.
Issuer Forecast Upside
Wallstreet Target Price 129.9 11.7%
Analysts Target Price 110.7 -4.8%
ValueRay Target Price 122 4.9%